LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 173

Search options

  1. Book ; Online ; E-Book: Asthma

    Pelaia, Girolamo / Vatrella, Alessandro / Maselli, Rosario

    targeted biological therapies

    2017  

    Author's details Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli
    Keywords Asthma / drug therapy ; Biological Therapy ; Precision Medicine
    Language English
    Size 1 Online-Ressource (vi, 99 Seiten), Illustrationen
    Publisher Springer
    Publishing place Cham
    Publishing country Switzerland
    Document type Book ; Online ; E-Book
    Note Includes bibliographical references
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT019469570
    ISBN 978-3-319-46007-9 ; 9783319460055 ; 3-319-46007-2 ; 3319460056
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Article: Editorial: Impact of system biology and molecular medicine on the management of complex immune mediated respiratory diseases, volume II.

    Cárdaba, Blanca / Pelaia, Girolamo

    Frontiers in medicine

    2023  Volume 10, Page(s) 1187941

    Language English
    Publishing date 2023-06-07
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2023.1187941
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Do Comorbidities Influence the Response to Biologics in Severe Asthma?

    Pelaia, Corrado / Pelaia, Girolamo / Busse, William

    American journal of respiratory and critical care medicine

    2023  Volume 209, Issue 3, Page(s) 233–235

    MeSH term(s) Humans ; Biological Products/therapeutic use ; Asthma/drug therapy ; Asthma/epidemiology ; Comorbidity
    Chemical Substances Biological Products
    Language English
    Publishing date 2023-12-08
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 1180953-x
    ISSN 1535-4970 ; 0003-0805 ; 1073-449X
    ISSN (online) 1535-4970
    ISSN 0003-0805 ; 1073-449X
    DOI 10.1164/rccm.202311-2103ED
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Editorial

    Blanca Cárdaba / Girolamo Pelaia

    Frontiers in Medicine, Vol

    Impact of system biology and molecular medicine on the management of complex immune mediated respiratory diseases, volume II

    2023  Volume 10

    Keywords asthma ; chronic obstructive pulmonary disease ; respiratory inflammation ; biological therapies asthma ; COVID ; metabolomic ; Medicine (General) ; R5-920
    Language English
    Publishing date 2023-06-01T00:00:00Z
    Publisher Frontiers Media S.A.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Publisher Correction to: An integrated metabo‑lipidomics profile of induced sputum for the identification of novel biomarkers in the differential diagnosis of asthma and COPD.

    Correnti, Serena / Preianò, Mariaimmacolata / Gamboni, Fabia / Stephenson, Daniel / Pelaia, Corrado / Pelaia, Girolamo / Savino, Rocco / D'Alessandro, Angelo / Terracciano, Rosa

    Journal of translational medicine

    2024  Volume 22, Issue 1, Page(s) 334

    Language English
    Publishing date 2024-04-05
    Publishing country England
    Document type Published Erratum
    ZDB-ID 2118570-0
    ISSN 1479-5876 ; 1479-5876
    ISSN (online) 1479-5876
    ISSN 1479-5876
    DOI 10.1186/s12967-024-05139-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Editorial: Impact of System Biology and Molecular Medicine on the Management of Complex Immune Mediated Respiratory Diseases.

    Cárdaba, Blanca / Pelaia, Girolamo

    Frontiers in medicine

    2021  Volume 8, Page(s) 745739

    Language English
    Publishing date 2021-09-08
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2021.745739
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Biologicals decrease psychological distress, anxiety and depression in severe asthma, despite Covid-19 pandemic.

    Patella, Vincenzo / Pelaia, Corrado / Zunno, Roberta / Pelaia, Girolamo

    Respiratory medicine

    2022  Volume 200, Page(s) 106916

    Abstract: Patients with respiratory diseases suffer more from problems of severe psychiatric comorbidity than the general population. Asthma might cause psychiatric disorders and affect patients' quality of life negatively. Previous studies reported that mental ... ...

    Abstract Patients with respiratory diseases suffer more from problems of severe psychiatric comorbidity than the general population. Asthma might cause psychiatric disorders and affect patients' quality of life negatively. Previous studies reported that mental disorders prevail in asthmatic patients, causing anxiety, depression, and suicidal risk. The aim of this study is to evaluate in real life the prevalence of psychological comorbidities in asthmatics with severe asthma treated by biologicals (Benralizumab, Mepolizumab, Omalizumab). This study starts with the hypothesis that psychological distress, anxiety, depression and suicidal risk in severe asthma patients decreases if treated by biologicals. This study involves a sample of 90 patients (32 males, 58 females and aged 53.92 ± 15.92) suffering from severe asthma and treated with the biological drugs of Benralizumab, Mepolizumab, Omalizumab during Covid-19 pandemic. At the beginning of the treatment (T0) and after 16 weeks (T1), there have been reported results from both clinical disease control, assessed using the ACT, and psychological disorders, assessed with the PSS, HADS and C-SSRS. In the sample of these patients treated with biologicals for severe asthma, the study reported a significant change in all observed parameters, including asthma control (ACT), stress (PSS), anxiety (HADS-A) and depressive symptoms (HADS-D, despite Covid-19 pandemic. In addition, there was a significant improvement in disease management, perceived stress, anxiety and depressive symptoms after a 16 week treatment for severe asthma, independent from the type of biologic drugs used during the pandemic.
    MeSH term(s) Anxiety/drug therapy ; Anxiety/epidemiology ; Anxiety/etiology ; Asthma/drug therapy ; Asthma/epidemiology ; Biological Products/therapeutic use ; COVID-19/complications ; COVID-19/drug therapy ; COVID-19/epidemiology ; Depression/diagnosis ; Depression/drug therapy ; Depression/epidemiology ; Female ; Humans ; Male ; Omalizumab ; Pandemics ; Psychological Distress ; Quality of Life ; SARS-CoV-2 ; Stress, Psychological/psychology
    Chemical Substances Biological Products ; Omalizumab (2P471X1Z11)
    Language English
    Publishing date 2022-06-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 1003348-8
    ISSN 1532-3064 ; 0954-6111
    ISSN (online) 1532-3064
    ISSN 0954-6111
    DOI 10.1016/j.rmed.2022.106916
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Editorial

    Blanca Cárdaba / Girolamo Pelaia

    Frontiers in Medicine, Vol

    Impact of System Biology and Molecular Medicine on the Management of Complex Immune Mediated Respiratory Diseases

    2021  Volume 8

    Keywords asthma ; chronic obstructive pulmonary disease ; COPD ; respiratory inflammation ; systems biology ; biological therapies ; Medicine (General) ; R5-920
    Language English
    Publishing date 2021-09-01T00:00:00Z
    Publisher Frontiers Media S.A.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: An integrated metabo-lipidomics profile of induced sputum for the identification of novel biomarkers in the differential diagnosis of asthma and COPD.

    Correnti, Serena / Preianò, Mariaimmacolata / Gamboni, Fabia / Stephenson, Daniel / Pelaia, Corrado / Pelaia, Girolamo / Savino, Rocco / D'Alessandro, Angelo / Terracciano, Rosa

    Journal of translational medicine

    2024  Volume 22, Issue 1, Page(s) 301

    Abstract: Background: Due to their complexity and to the presence of common clinical features, differentiation between asthma and chronic obstructive pulmonary disease (COPD) can be a challenging task, complicated in such cases also by asthma-COPD overlap ... ...

    Abstract Background: Due to their complexity and to the presence of common clinical features, differentiation between asthma and chronic obstructive pulmonary disease (COPD) can be a challenging task, complicated in such cases also by asthma-COPD overlap syndrome. The distinct immune/inflammatory and structural substrates of COPD and asthma are responsible for significant differences in the responses to standard pharmacologic treatments. Therefore, an accurate diagnosis is of central relevance to assure the appropriate therapeutic intervention in order to achieve safe and effective patient care. Induced sputum (IS) accurately mirrors inflammation in the airways, providing a more direct picture of lung cell metabolism in comparison to those specimen that reflect analytes in the systemic circulation.
    Methods: An integrated untargeted metabolomics and lipidomics analysis was performed in IS of asthmatic (n = 15) and COPD (n = 22) patients based on Ultra-High-Pressure Liquid Chromatography-Mass Spectrometry (UHPLC-MS) and UHPLC-tandem MS (UHPLC-MS/MS). Partial Least Squares-Discriminant Analysis (PLS-DA) was applied to resulting dataset. The analysis of main enriched metabolic pathways and the association of the preliminary metabolites/lipids pattern identified to clinical parameters of asthma/COPD differentiation were explored. Multivariate ROC analysis was performed in order to determine the discriminatory power and the reliability of the putative biomarkers for diagnosis between COPD and asthma.
    Results: PLS-DA indicated a clear separation between COPD and asthmatic patients. Among the 15 selected candidate biomarkers based on Variable Importance in Projection scores, putrescine showed the highest score. A differential IS bio-signature of 22 metabolites and lipids was found, which showed statistically significant variations between asthma and COPD. Of these 22 compounds, 18 were decreased and 4 increased in COPD compared to asthmatic patients. The IS levels of Phosphatidylethanolamine (PE) (34:1), Phosphatidylglycerol (PG) (18:1;18:2) and spermine were significantly higher in asthmatic subjects compared to COPD.
    Conclusions: This is the first pilot study to analyse the IS metabolomics/lipidomics signatures relevant in discriminating asthma vs COPD. The role of polyamines, of 6-Hydroxykynurenic acid and of D-rhamnose as well as of other important players related to the alteration of glycerophospholipid, aminoacid/biotin and energy metabolism provided the construction of a diagnostic model that, if validated on a larger prospective cohort, might be used to rapidly and accurately discriminate asthma from COPD.
    MeSH term(s) Humans ; Lipidomics ; Tandem Mass Spectrometry/methods ; Sputum/metabolism ; Diagnosis, Differential ; Reproducibility of Results ; Pilot Projects ; Prospective Studies ; Pulmonary Disease, Chronic Obstructive ; Asthma/diagnosis ; Asthma/metabolism ; Biomarkers ; Metabolomics/methods ; Lipids
    Chemical Substances Biomarkers ; Lipids
    Language English
    Publishing date 2024-03-23
    Publishing country England
    Document type Journal Article
    ZDB-ID 2118570-0
    ISSN 1479-5876 ; 1479-5876
    ISSN (online) 1479-5876
    ISSN 1479-5876
    DOI 10.1186/s12967-024-05100-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Effects of inhaled beclomethasone dipropionate/formoterol fumarate/glycopyrronium on diaphragmatic workload and lung function in uncontrolled asthma: a case report.

    Maiorano, Antonio / Lupia, Chiara / Montenegro, Nicola / Neri, Giuseppe / Bruni, Andrea / Garofalo, Eugenio / Longhini, Federico / Crimi, Claudia / Maglio, Angelantonio / Vatrella, Alessandro / Pelaia, Girolamo / Pelaia, Corrado

    Frontiers in medicine

    2024  Volume 11, Page(s) 1357362

    Abstract: Beclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) single inhaler extrafine triple therapy is effective for the treatment of uncontrolled asthma. Nevertheless, there is a lack of data about the use of diaphragmatic ultrasonography ... ...

    Abstract Beclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) single inhaler extrafine triple therapy is effective for the treatment of uncontrolled asthma. Nevertheless, there is a lack of data about the use of diaphragmatic ultrasonography to monitor adult asthmatics while they are receiving inhaled treatment. We took into consideration a 78-year-old woman complaining of asthma, treated with inhaled corticosteroid/long-acting β
    Language English
    Publishing date 2024-03-05
    Publishing country Switzerland
    Document type Case Reports
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2024.1357362
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top